Pharmaceutical product comprising a muscarinic receptor antagonist and a beta2-adrenoceptor agonist

A technology of receptor agonists and pharmaceutical products, applied in the direction of medical preparations containing active ingredients, drug combinations, pharmaceutical formulations, etc., can solve problems such as unsatisfactory drug efficacy

Inactive Publication Date: 2011-06-08
ASTRAZENECA AB +1
View PDF14 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0009] Although using beta 2 Treatment with adrenoceptor agonists or muscarinic antagonis

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical product comprising a muscarinic receptor antagonist and a beta2-adrenoceptor agonist
  • Pharmaceutical product comprising a muscarinic receptor antagonist and a beta2-adrenoceptor agonist
  • Pharmaceutical product comprising a muscarinic receptor antagonist and a beta2-adrenoceptor agonist

Examples

Experimental program
Comparison scheme
Effect test

Example Embodiment

[0164] Preparation of muscarinic antagonist

[0165] The muscarinic antagonist of the present invention can be prepared as follows. Alternative salts of those described in this application can be prepared by conventional chemical action using methods similar to those described.

[0166] General experimental details for dry preparation of muscarinic antagonists

[0167] Unless otherwise specified, the following general conditions are used in the preparation of muscarinic antagonists.

[0168] Unless otherwise specified, all reactions were performed under a nitrogen atmosphere.

[0169] In the embodiment, the NMR spectrum is measured on a Varian Unity Inova spectrometer with a proton frequency of 300 or 400 or 500MHz, or on a Bruker DRX spectrometer with a proton frequency of 400 or 500MHz, or on a BrukerAvance spectrometer with a proton frequency of 600MHz The frequency is measured, or on a Bruker Avance DPX 300 spectrometer at a proton frequency of 300MHz. The MS spectrum was measur...

Example Embodiment

[0199] Example 1: (R)-3-(1-Phenyl-cycloheptanecarbonyloxy)-1-(pyrazin-2-ylcarbamoylmethyl)-1-nitrogen -Bicyclo[2.2.2]octane bromide

[0200] a) 1-Phenyl-cycloheptanol

[0201]

[0202] To a solution of magnesium (1.2 g) in anhydrous tetrahydrofuran (60 mL), crystals of iodine were added to a solution of magnesium (1.2 g) in anhydrous tetrahydrofuran (60 mL) under a nitrogen atmosphere at a rate at which the reaction maintained stable reflux, followed by bromobenzene (7.85 g). The reaction mixture was stirred for 20 minutes and then cycloheptanone (4.48 g) was carefully added. After stirring for 10 minutes, saturated aqueous ammonium chloride (10 mL) was added and the reaction mixture was partitioned between water (100 mL) and isohexane (100 mL). Dry the organic layer (MgSO 4 ) And evaporation to give the subtitle compound (7.6g) as an oil.

[0203] 1 H NMR(299.946MHz, CDCl 3 )δ7.53-7.47 (m, 2H), 7.36-7.29 (m, 2H), 7.26-7.19 (m, 1H), 2.07 (ddd, 2H), 1.97-1.50 (m, 11H).

[0204] b) 1...

Example

[0230] For Example 1: (R)-3-(1-phenyl-cycloheptanecarbonyloxy)-1-(pyrazin-2-ylcarbamoylmethyl)-1-nitrogen -Analysis of Bicyclo[2.2.2]octane Bromide Form A

[0231] The sample of crystal form A of Example 1 obtained by the above operation was analyzed by XRPD (PANalytical X'Pert or CubiX system), DSC and TGA.

[0232] The melting temperature of the bromide crystal form A of Example 1 determined by DSC was actually 202°C (initial) (±2°C). The weight loss observed by TGA before melting was 2.7%. GVS determined to obtain a 3% weight gain (%w / w) (±0.2%) at 80%RH.

[0233] Example 1 The XRPD spectrum of bromide crystal form A is in figure 1 Show in.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention provides a pharmaceutical product, kit or composition comprising a first active ingredient which is a selected muscarinic receptor antagonist, and a second active ingredient which is a Beta2-adrenoceptor agonist, of use in the treatment of respiratory diseases such as chronic obstructive pulmonary disease and asthma.

Description

technical field [0001] The present invention relates to combinations of pharmaceutically active substances for the treatment of respiratory diseases, in particular chronic obstructive pulmonary disease (COPD) and asthma. Background technique [0002] The essential function of the lung requires a delicate structure to be exposed extensively to the environment including pollutants, microorganisms, allergens and carcinogens. Host factors arising from the interplay of lifestyle choices and genetic makeup influence the response to this exposure. Injury or infection to the lungs can produce a wide range of respiratory disorders (or respiratory diseases). Many of these diseases are of enormous public health importance. Respiratory diseases include acute lung injury, acute respiratory distress syndrome (ARDS), occupational lung disease, lung cancer, tuberculosis, fibrosis, pneumoconiosis, pneumonia, emphysema, chronic obstructive pulmonary disease (COPD), and asthma . [0003] T...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/439A61P11/06A61P11/08A61K31/428
CPCA61K45/06A61K31/439A61K31/428A61P11/00A61P11/06A61P11/08A61P43/00A61K2300/00
Inventor 理查德·布尔罗南·福特安德鲁·马瑟安东尼奥·梅特凯瑟琳·威利
Owner ASTRAZENECA AB
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products